Kinarus AG is a clinical-stage pharmaceutical company focused on bringing novel, patient-focused treatments to those suffering from viral, respiratory, and ophthalmic diseases.
Kinarus was incorporated in Basel, Switzerland, in 2017. Its therapeutic asset KIN001 is made up of a P38 MAPK inhibitor, in-licensed from Roche, and a second drug, together enabling an oral, long-term effective treatment for patients with life threatening diseases and diseases with serious impact on quality of life.
Recently, in response to the global challenge of Covid-19, Kinarus adopted its combination therapy to treat Covid-19 patients. KIN001 is potentially an effective antiviral agent as well as effective treatment for inflammatory and fibrotic consequences, together addressing both the acute and long-term effects of Covid-19.